​

Thermo Fisher Scientific (TMO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TMO Stock Forecast

Thermo Fisher Scientific stock forecast is as follows: an average price target of $640.88 (represents a 22.29% upside from TMO’s last price of $524.05) and a rating consensus of 'Buy', based on 18 wall street analysts offering a 1-year stock forecast.

TMO Price Target

The average price target for Thermo Fisher Scientific (TMO) is $640.88 based on 1-year price targets from 18 Wall Street analysts in the past 3 months, with a price target range of $680.00 to $610.00. This represents a potential 22.29% upside from TMO's last price of $524.05.

TMO Analyst Ratings

Buy

According to 18 Wall Street analysts, Thermo Fisher Scientific's rating consensus is 'Buy'. The analyst rating breakdown for TMO stock is 0 'Strong Buy' (0.00%), 15 'Buy' (83.33%), 3 'Hold' (16.67%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Thermo Fisher Scientific Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 24, 2024Catherine SchulteRobert W. Baird$622.00$576.497.89%18.69%
Oct 23, 2024Luke SergottBarclays$610.00$570.926.85%16.40%
Oct 01, 2024Vijay KumarEvercore ISI$630.00$618.571.85%20.22%
Sep 20, 2024Daniel AriasStifel Nicolaus$680.00$620.259.63%29.76%
Sep 20, 2024Catherine SchulteRobert W. Baird$632.00$620.251.89%20.60%
Sep 19, 2024Patrick DonnellyCitigroup$620.00$617.110.47%18.31%
Sep 18, 2024Justin BowersDeutsche Bank$630.00$609.413.38%20.22%
Sep 16, 2024Derik de BruinBank of America Securities$675.00$611.1710.44%28.80%
Jul 25, 2024Andrew CooperRaymond James$660.00$593.8611.14%25.94%
Jun 28, 2024Luke SergottBarclays$600.00$550.788.94%14.49%
Apr 30, 2024Sidharth SahooHSBC$670.00$576.8916.14%27.85%
Apr 25, 2024Justin BowersDeutsche Bank$610.00$577.395.65%16.40%
Apr 25, 2024Luke SergottBarclays$615.00$577.396.51%17.36%
Dec 28, 2023Catherine SchulteRobert W. Baird$670.00$531.6526.02%27.85%
Oct 26, 2023Andrew CooperRaymond James$530.00$444.4519.25%1.14%
Jul 13, 2023Thermo FisherCredit Suisse$620.00$525.6317.95%18.31%
Feb 02, 2023Cowen & Co.$711.00$591.9520.11%35.67%
Feb 02, 2023Citigroup$700.00$589.7318.70%33.58%
Feb 02, 2023Barclays$660.00$587.3612.37%25.94%
Feb 02, 2023Leerink Partners$630.00$587.367.26%20.22%
Jan 06, 2023Leerink Partners$620.00$532.8816.35%18.31%
Jan 03, 2023Wells Fargo$505.00$553.18-8.71%-3.64%
Dec 14, 2022Deutsche Bank$620.00$571.388.51%18.31%
Dec 07, 2022RBC Capital$661.00$550.5320.07%26.13%
Nov 29, 2022Barclays$570.00$540.035.55%8.77%
Sep 12, 2022Barclays$595.00$569.404.50%13.54%
Aug 04, 2022Luke SergottBarclays$685.00$587.9816.50%30.71%
Jul 29, 2022Morgan Stanley$678.00$606.2411.84%29.38%
Jul 29, 2022Leerink Partners$650.00$597.648.76%24.03%
Jul 13, 2022Barclays$630.00$530.9318.66%20.22%
Apr 29, 2022Morgan Stanley$670.00$563.7918.84%27.85%
Apr 25, 2022Wells Fargo$525.00$561.28-6.46%0.18%
Oct 28, 2021Tejas SavantMorgan Stanley$700.00$619.4713.00%33.58%
Oct 27, 2021Robert WassermanBenchmark Co.$650.00$611.706.26%24.03%
Sep 23, 2021Matthew SykesGoldman Sachs$690.00$607.6413.55%31.67%
Sep 20, 2021Derik De BruinBank of America Securities$670.00$589.6313.63%27.85%
Sep 20, 2021Brandon CouillardJefferies$540.00$589.63-8.42%3.04%
Sep 20, 2021Tycho PetersonJ.P. Morgan$700.00$589.6318.72%33.58%
Sep 20, 2021Paul KnightKeyBanc$710.00$589.6320.41%35.48%
Aug 04, 2021David ToungArgus Research$600.00$538.1111.50%14.49%

The latest Thermo Fisher Scientific stock forecast, released on Oct 24, 2024 by Catherine Schulte from Robert W. Baird, set a price target of $622.00, which represents a 7.89% increase from the stock price at the time of the forecast ($576.49), and a 18.69% increase from TMO last price ($524.05).

Thermo Fisher Scientific Price Target by Period

1M3M12M
# Anlaysts-714
Avg Price Target-$632.00$637.43
Last Closing Price$524.05$524.05$524.05
Upside/Downside-100.00%20.60%21.64%

In the current month, the average price target of Thermo Fisher Scientific stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Thermo Fisher Scientific's last price of $524.05. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Oct 15, 2024BarclaysEqual-WeightEqual-WeightHold
Oct 01, 2024Evercore ISIOutperformOutperformHold
Sep 30, 2024StephensOverweightInitialise
Sep 20, 2024Morgan StanleyOverweightOverweightHold
Sep 20, 2024Cowen & Co.BuyBuyHold
Sep 19, 2024CitigroupNeutralNeutralHold
Sep 18, 2024Deutsche BankBuyBuyHold
Sep 16, 2024Bank of America SecuritiesBuyBuyHold
Aug 27, 2024Wells FargoUnderweightOverweightInitialise
Jul 25, 2024Raymond JamesOutperformOutperformHold
Jul 25, 2024Cowen & Co.BuyBuyHold
Jul 24, 2024Goldman SachsBuyBuyHold
Jun 28, 2024BarclaysEqual-WeightEqual-WeightHold
Jun 03, 2024JefferiesBuyUpgrade
Apr 25, 2024RBC CapitalOutperformOutperformHold
Apr 25, 2024Cowen & Co.BuyBuyHold
Apr 25, 2024Deutsche BankBuyBuyHold
Apr 25, 2024BarclaysEqual-WeightEqual-WeightHold
Apr 17, 2024HSBCBuyBuyHold
Mar 25, 2024CFRABuyUpgrade
Feb 01, 2024RBC CapitalOutperformOutperformHold
Dec 28, 2023Morgan StanleyEqual-WeightEqual-WeightHold
Dec 11, 2023CitigroupBuyBuyHold
Oct 26, 2023RBC CapitalOutperformOutperformHold
Oct 26, 2023BarclaysOverweightOverweightHold
Oct 26, 2023RBC CapitalOutperformSector WeightDowngrade
Oct 26, 2023Morgan StanleyOverweightOverweightHold
Oct 26, 2023CitigroupBuyBuyHold
Oct 26, 2023Raymond JamesOutperformOutperformHold
Oct 26, 2023KeyBancSector WeightDowngrade
Jul 13, 2023Credit SuisseOutperformUpgrade
Feb 02, 2023Cowen & Co.OutperformOutperformHold
Feb 02, 2023CitigroupBuyBuyHold
Feb 02, 2023BarclaysOverweightOverweightHold
Feb 02, 2023SVB LeerinkOutperformOutperformHold
Jan 06, 2023SVB LeerinkOutperformOutperformHold
Jan 03, 2023Wells FargoUnderweightUnderweightHold
Dec 14, 2022Deutsche BankBuyInitialise
Dec 07, 2022RBC CapitalOutperformInitialise
Nov 29, 2022BarclaysOverweightOverweightHold
Oct 27, 2022SVB LeerinkOutperformOutperformHold
Sep 12, 2022BarclaysOverweightOverweightHold
Aug 04, 2022BarclaysOverweightOverweightHold
Jul 29, 2022Morgan StanleyOverweightOverweightHold
Jul 29, 2022SVB LeerinkOutperformOutperformHold
Jul 13, 2022BarclaysOverweightOverweightHold
Apr 29, 2022Morgan StanleyOverweightOverweightHold
Apr 25, 2022Wells FargoUnderweightDowngrade

Thermo Fisher Scientific's last stock rating was published by Barclays on Oct 15, 2024. The company gave TMO a "Equal-Weight" rating, the same as its previous rate.

Thermo Fisher Scientific Financial Forecast

Thermo Fisher Scientific Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue------------$10.89B$10.57B$10.69B$10.71B$11.45B$10.68B$10.97B$11.82B$10.70B$9.33B$9.27B$9.91B$10.55B$8.52B$6.92B$6.23B$6.83B$6.27B
Avg Forecast$12.93B$12.06B$11.94B$11.62B$11.92B$11.16B$11.08B$10.77B$11.29B$10.63B$10.50B$10.15B$10.73B$10.60B$10.99B$10.65B$10.43B$9.94B$9.97B$10.69B$8.71B$8.38B$8.73B$9.72B$9.58B$7.65B$6.10B$6.17B$6.78B$6.18B
High Forecast$13.10B$12.23B$12.10B$11.77B$12.08B$11.31B$11.23B$10.89B$11.40B$10.63B$10.50B$10.15B$10.77B$10.75B$11.14B$10.80B$10.57B$9.94B$9.97B$10.69B$8.71B$8.38B$8.73B$9.72B$9.58B$7.65B$6.10B$6.17B$6.78B$6.18B
Low Forecast$12.76B$11.91B$11.78B$11.47B$11.76B$11.02B$10.93B$10.66B$11.12B$10.63B$10.50B$10.15B$10.70B$10.39B$10.85B$10.51B$10.29B$9.94B$9.97B$10.69B$8.71B$8.38B$8.73B$9.72B$9.58B$7.65B$6.10B$6.17B$6.78B$6.18B
# Analysts777766610136549181398158999129910101099
Surprise %------------1.01%1.00%0.97%1.01%1.10%1.07%1.10%1.11%1.23%1.11%1.06%1.02%1.10%1.11%1.13%1.01%1.01%1.01%

Thermo Fisher Scientific's average Quarter revenue forecast for Mar 24 based on 4 analysts is $10.15B, with a low forecast of $10.15B, and a high forecast of $10.15B. TMO's average Quarter revenue forecast represents a -6.72% decrease compared to the company's last Quarter revenue of $10.89B (Dec 23).

Thermo Fisher Scientific EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts777766610136549181398158999129910101099
EBITDA------------$1.85B$3.06B$2.79B$2.63B$2.95B$2.65B$2.92B$3.54B$2.71B$2.93B$2.83B$3.50B$3.64B$2.97B$1.96B$1.53B$1.76B$1.56B
Avg Forecast$3.69B$3.44B$3.41B$3.32B$3.40B$3.18B$3.16B$3.07B$3.22B$3.04B$3.00B$2.56B$3.06B$3.03B$3.14B$2.32B$1.92B$2.79B$2.80B$1.84B$2.05B$2.35B$2.45B$2.73B$2.69B$2.15B$1.71B$1.45B$1.90B$1.74B
High Forecast$3.74B$3.49B$3.45B$3.36B$3.45B$3.23B$3.20B$3.11B$3.25B$3.04B$3.00B$3.07B$3.07B$3.07B$3.18B$2.79B$2.30B$2.79B$2.80B$2.20B$2.46B$2.35B$2.45B$2.73B$2.69B$2.15B$1.71B$1.74B$1.90B$1.74B
Low Forecast$3.64B$3.40B$3.36B$3.27B$3.36B$3.14B$3.12B$3.04B$3.17B$3.04B$3.00B$2.04B$3.05B$2.96B$3.10B$1.86B$1.54B$2.79B$2.80B$1.47B$1.64B$2.35B$2.45B$2.73B$2.69B$2.15B$1.71B$1.16B$1.90B$1.74B
Surprise %------------0.61%1.01%0.89%1.13%1.54%0.95%1.04%1.93%1.32%1.24%1.15%1.28%1.35%1.38%1.15%1.05%0.92%0.90%

4 analysts predict TMO's average Quarter EBITDA for Mar 24 to be $2.56B, with a high of $3.07B and a low of $2.04B. This is 37.82% upper than Thermo Fisher Scientific's previous annual EBITDA (Dec 23) of $1.85B.

Thermo Fisher Scientific Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts777766610136549181398158999129910101099
Net Income------------$1.63B$1.72B$1.36B$1.29B$1.58B$1.50B$1.66B$2.21B$1.67B$1.90B$1.83B$2.34B$2.50B$1.93B$1.16B$788.00M$1.00B$760.00M
Avg Forecast$2.79B$2.45B$2.40B$2.28B$2.50B$2.20B$2.17B$2.07B$2.29B$2.01B$1.97B$1.32B$2.17B$2.15B$2.08B$1.20B$1.18B$1.85B$1.91B$946.98M$1.26B$1.79B$2.09B$2.55B$2.51B$1.66B$1.11B$748.60M$1.36B$1.10B
High Forecast$2.84B$2.50B$2.45B$2.32B$2.54B$2.24B$2.21B$2.15B$2.31B$2.01B$1.97B$1.58B$2.20B$2.21B$2.12B$1.44B$1.41B$1.85B$1.91B$1.14B$1.51B$1.79B$2.09B$2.55B$2.51B$1.66B$1.11B$898.32M$1.36B$1.10B
Low Forecast$2.75B$2.41B$2.36B$2.24B$2.46B$2.17B$2.13B$1.99B$2.20B$2.01B$1.97B$1.05B$2.16B$2.09B$2.05B$958.34M$941.32M$1.85B$1.91B$757.58M$1.01B$1.79B$2.09B$2.55B$2.51B$1.66B$1.11B$598.88M$1.36B$1.10B
Surprise %------------0.75%0.80%0.65%1.08%1.34%0.81%0.87%2.34%1.32%1.06%0.87%0.92%0.99%1.17%1.04%1.05%0.74%0.69%

Thermo Fisher Scientific's average Quarter net income forecast for Mar 24 is $1.32B, with a range of $1.05B to $1.58B. TMO's average Quarter net income forecast represents a -19.16% decrease compared to the company's last Quarter net income of $1.63B (Dec 23).

Thermo Fisher Scientific SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts777766610136549181398158999129910101099
SG&A------------$1.67B$1.58B$1.67B$1.65B$1.84B$1.74B$1.74B$1.81B$2.28B$2.00B$1.90B$1.83B$2.08B$1.59B$1.71B$1.55B$1.51B$1.54B
Avg Forecast$2.33B$2.18B$2.15B$2.10B$2.15B$2.01B$2.00B$1.94B$2.04B$1.92B$1.90B$2.59B$1.94B$1.91B$1.98B$2.36B$1.62B$1.71B$1.71B$1.86B$1.73B$1.44B$1.50B$1.67B$1.64B$1.31B$1.05B$1.47B$1.16B$1.06B
High Forecast$2.36B$2.21B$2.18B$2.12B$2.18B$2.04B$2.03B$1.97B$2.06B$1.92B$1.90B$3.11B$1.94B$1.94B$2.01B$2.83B$1.94B$1.71B$1.71B$2.24B$2.07B$1.44B$1.50B$1.67B$1.64B$1.31B$1.05B$1.77B$1.16B$1.06B
Low Forecast$2.30B$2.15B$2.13B$2.07B$2.12B$1.99B$1.97B$1.92B$2.01B$1.92B$1.90B$2.07B$1.93B$1.87B$1.96B$1.89B$1.29B$1.71B$1.71B$1.49B$1.38B$1.44B$1.50B$1.67B$1.64B$1.31B$1.05B$1.18B$1.16B$1.06B
Surprise %------------0.86%0.83%0.84%0.70%1.14%1.02%1.02%0.97%1.32%1.39%1.27%1.09%1.26%1.21%1.63%1.05%1.30%1.45%

Thermo Fisher Scientific's average Quarter SG&A projection for Mar 24 is $2.59B, based on 4 Wall Street analysts, with a range of $2.07B to $3.11B. The forecast indicates a 55.12% rise compared to TMO last annual SG&A of $1.67B (Dec 23).

Thermo Fisher Scientific EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts777766610136549181398158999129910101099
EPS------------$4.21$4.44$3.53$3.34$4.03$3.82$4.25$5.66$4.23$4.83$4.65$5.93$6.30$4.88$2.92$1.99$2.51$1.89
Avg Forecast$7.28$6.39$6.26$5.94$6.51$5.74$5.65$5.40$5.95$5.24$5.12$4.71$5.64$5.61$5.42$5.03$5.20$4.83$4.99$6.22$4.93$4.68$5.47$6.66$6.56$4.33$2.89$2.80$3.54$2.87
High Forecast$7.40$6.50$6.37$6.04$6.62$5.84$5.75$5.60$6.01$5.25$5.12$4.71$5.73$5.76$5.52$5.12$5.29$4.83$4.99$6.22$4.93$4.68$5.47$6.66$6.56$4.33$2.89$2.80$3.54$2.87
Low Forecast$7.15$6.28$6.16$5.84$6.40$5.65$5.56$5.18$5.73$5.24$5.12$4.71$5.62$5.43$5.33$4.94$5.11$4.83$4.99$6.22$4.93$4.68$5.47$6.66$6.56$4.33$2.89$2.80$3.54$2.87
Surprise %------------0.75%0.79%0.65%0.66%0.78%0.79%0.85%0.91%0.86%1.03%0.85%0.89%0.96%1.13%1.01%0.71%0.71%0.66%

According to 4 Wall Street analysts, Thermo Fisher Scientific's projected average Quarter EPS for Mar 24 is $4.71, with a low estimate of $4.71 and a high estimate of $4.71. This represents a 11.85% increase compared to TMO previous annual EPS of $4.21 (Dec 23).

Thermo Fisher Scientific Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
DHRDanaher$233.53$292.4025.21%Buy
TMOThermo Fisher Scientific$528.84$640.8821.19%Buy
IDXXIDEXX Laboratories$427.09$510.0019.41%Buy
GHGuardant Health$34.84$40.6016.53%Buy
MTDMettler-Toledo$1.25K$1.41K13.28%Hold
RVTYRevvity$114.75$127.8611.42%Buy
CRLCharles River Laboratories$189.33$209.0010.39%Buy
AAgilent$136.46$147.408.02%Buy
ILMNIllumina$143.12$147.783.26%Buy
WATWaters$373.72$356.80-4.53%Buy

TMO Forecast FAQ

Is Thermo Fisher Scientific a good buy?

Yes, according to 18 Wall Street analysts, Thermo Fisher Scientific (TMO) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 15 'Buy' recommendations, accounting for 83.33% of TMO's total ratings.

What is TMO's price target?

Thermo Fisher Scientific (TMO) average price target is $640.88 with a range of $610 to $680, implying a 22.29% from its last price of $524.05. The data is based on 18 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Thermo Fisher Scientific stock go up soon?

According to Wall Street analysts' prediction for TMO stock, the company can go up by 22.29% (from the last price of $524.05 to the average price target of $640.88), up by 29.76% based on the highest stock price target, and up by 16.40% based on the lowest stock price target.

Can Thermo Fisher Scientific stock reach $800?

TMO's average twelve months analyst stock price target of $640.88 does not support the claim that Thermo Fisher Scientific can reach $800 in the near future.

What are Thermo Fisher Scientific's analysts' financial forecasts?

Thermo Fisher Scientific's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $44.92B (high $45.51B, low $44.37B), average EBITDA is $12.82B (high $12.99B, low $12.67B), average net income is $8.95B (high $9.15B, low $8.75B), average SG&A $8.11B (high $8.21B, low $8.01B), and average EPS is $23.3 (high $23.82, low $22.78). TMO's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $48.54B (high $49.2B, low $47.92B), average EBITDA is $13.85B (high $14.04B, low $13.68B), average net income is $9.93B (high $10.11B, low $9.76B), average SG&A $8.76B (high $8.88B, low $8.65B), and average EPS is $25.86 (high $26.32, low $25.43).

Did the TMO's actual financial results beat the analysts' financial forecasts?

Based on Thermo Fisher Scientific's last annual report (Dec 2023), the company's revenue was $42.86B, which missed the average analysts forecast of $42.97B by -0.27%. Apple's EBITDA was $6.86B, missing the average prediction of $11.55B by -40.60%. The company's net income was $6B, missing the average estimation of $7.6B by -21.14%. Apple's SG&A was $6.57B, missing the average forecast of $8.19B by -19.79%. Lastly, the company's EPS was $15.53, missing the average prediction of $21.71 by -28.45%. In terms of the last quarterly report (Dec 2023), Thermo Fisher Scientific's revenue was $10.89B, beating the average analysts' forecast of $10.73B by 1.43%. The company's EBITDA was $1.85B, missing the average prediction of $3.06B by -39.48%. Thermo Fisher Scientific's net income was $1.63B, missing the average estimation of $2.17B by -24.79%. The company's SG&A was $1.67B, missing the average forecast of $1.94B by -13.66%. Lastly, the company's EPS was $4.21, missing the average prediction of $5.64 by -25.41%